Needham analyst Ami Fadia raised the firm’s price target on Merus (MRUS) to $65 from $42 and keeps a Buy rating on the shares. The firm is also adding the name to its Conviction List in place of Avadel Pharmaceuticals (AVDL). Merus is enjoying greater investor enthusiasm around the upcoming data for Peto in first-line HNSCC, or head and neck squamous cell carcinoma, in combo with pembro, the analyst tells investors in a research note. Needham adds that its market model refresh estimates a sales potential for Peto of over $3B in first-line and over $850M in second-line HNSCC by 2035.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRUS:
- Merus price target raised to $54 from $45 at Canaccord
- Merus price target raised to $65 from $40 at Stifel
- Merus price target raised to $65 from $48 at H.C. Wainwright
- Merus files automatic mixed securities shelf
- Merus reports 2023 EPS ($3.00), consensus ($2.68)
Questions or Comments about the article? Write to editor@tipranks.com